- Home
- MIN vs CDTX Comparison
MIN vs CDTX Comparison
Compare MIN & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- CDTX
- Stock Information
- Founded
- MIN 1988
- CDTX 2012
- Country
- MIN United States
- CDTX United States
- Employees
- MIN N/A
- CDTX N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MIN Finance
- CDTX Health Care
- Exchange
- MIN Nasdaq
- CDTX Nasdaq
- Market Cap
- MIN 306.1M
- CDTX 259.0M
- IPO Year
- MIN N/A
- CDTX 2015
- Fundamental
- Price
- MIN $2.69
- CDTX $20.12
- Analyst Decision
- MIN
- CDTX Strong Buy
- Analyst Count
- MIN 0
- CDTX 8
- Target Price
- MIN N/A
- CDTX $38.00
- AVG Volume (30 Days)
- MIN 331.0K
- CDTX 108.4K
- Earning Date
- MIN 01-01-0001
- CDTX 05-08-2025
- Dividend Yield
- MIN 7.31%
- CDTX N/A
- EPS Growth
- MIN N/A
- CDTX N/A
- EPS
- MIN 0.08
- CDTX N/A
- Revenue
- MIN N/A
- CDTX $1,275,000.00
- Revenue This Year
- MIN N/A
- CDTX N/A
- Revenue Next Year
- MIN N/A
- CDTX N/A
- P/E Ratio
- MIN $33.38
- CDTX N/A
- Revenue Growth
- MIN N/A
- CDTX N/A
- 52 Week Low
- MIN $2.52
- CDTX $10.14
- 52 Week High
- MIN $2.88
- CDTX $28.42
- Technical
- Relative Strength Index (RSI)
- MIN 52.32
- CDTX 42.23
- Support Level
- MIN $2.65
- CDTX $19.97
- Resistance Level
- MIN $2.71
- CDTX $22.80
- Average True Range (ATR)
- MIN 0.03
- CDTX 1.42
- MACD
- MIN 0.00
- CDTX -0.13
- Stochastic Oscillator
- MIN 68.75
- CDTX 9.49
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.